Strides gets USFDA nod for Ibuprofen OTC oral suspension
February 24, 2021
×
Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules, topicals, powders and oral solutions
Strides Pharma Science Limited has announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL (OTC) from the United States Food & Drug Administration (USFDA).
Ibuprofen OTC Oral Suspension Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain from various conditions such as headache, dental pain, and muscle aches. It is also used to reduce fever and to relieve minor aches and pains due to the common cold or flu. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Children’s Motrin Oral Suspension, 100 mg/mL, of Johnson & Johnson Consumer Inc.
Strides Pharma receives approval for ibuprofen from USFDA dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.
India, Maldives foreign minister level talks Friday
K’taka: Kalaburagi, Bidar districts record 666 covid cases
Six arrested for highway robbery of around Rs 1 80 lakh
Jain pays surprise visit to LNJP Hospital amid Covid-19 surge
TMC is on way out from Bengal: Anurag Thakur
40-yr-old Covid recovered man jumps to death in front of Express train in Thane
Kerala reports 8,778 new COVID cases, 2,642 recoveries: Health Minister
UP sees over 20k nCoV cases for first time; 68 deaths
UP prepares for 1st phase of panchayat polls in 18 districts on Thursday
Complete lockdown in Chhattisgarh s Bastar to contain coronavirus
Strides Pharma gains 3 per cent on FDA approval for Prednisone Tablets
February 12, 2021
The product will be manufactured at Bengaluru facility
The shares of Strides Pharma Science Limited (Strides) gained 3 per cent during the afternoon trade on Friday after the company announced that it had received approval for Prednisone Tablets USP, 10 mg and 20 mg from the United States Food & Drug Administration (USFDA).
At 1:13 pm, Strides Pharma was trading at ₹895.40 on the BSE, up ₹29.60 or 3.42 per cent.
It hit an intraday high of ₹902.25 and an intraday low of ₹868.45. It opened at ₹873.25 as against the previous close of ₹865.80.
On the NSE, it was trading at ₹895.00, up ₹28.75 or 3.32 per cent. It hit an intraday high of ₹902.00 and an intraday low of ₹866.30.